We have based these forward-looking statements on our current expectations and projections about future events. Wellbutrin xl 150 mg biovail Corporation undertakes no obligation to update or revise any forward-looking statement. TORONTO -- Biovail Corporation (NYSE:BVF) (TSX:BVF) has been advised that GlaxoSmithKline (GSK) has received a Notice of Patent Certification associated with an abbreviated new drug application (ANDA) that has been submitted to the U. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "should," "would," "estimate," or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. Biovail developed the formulation for Wellbutrin XL(R) and licensed the product's worldwide (excluding Canada) sales and distribution rights to GlaxoSmithKline (GSK) in October 2001. "We are confident in the strength of our intellectual property rights as they relate to Wellbutrin XL(R), and wellbutrin xl 150 mg will defend these vigorously," said Dr. The active ingredient in Wellbutrin XL(R) -- bupropion hydrochloride -- is believed to act wellbutrin xl 150 mg upon norepinephrine and dopamine, two chemicals in the brain known to help regulate different aspects of mood, cognition, and behavior. Wellbutrin xl 150 mg glaxosmithkline markets Wellbutrin XL and for the treatment of depression. For more information, please visit the Company's Web site at: www. Impaxlabs.
Food and wellbutrin xl 150 mg drug Administration (FDA) under Paragraph IV of the Hatch-Waxman Amendments, stating that it believes its generic versions of Wellbutrin XL 150 and 300 mg tablets do not infringe Biovail's listed patents or that the listed patents are invalid or unenforceable. Patent numbers 6,143,327 and 6,096,341) listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations database (commonly referred to as the Orange Book).
Imbalances in these brain chemicals are associated with depressed mood and other symptoms wellbutrin xl 150 mg of depression.
Additionally, where strategically appropriate, IMPAX has developed marketing partnerships to fully leverage its technology platform. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including but not limited to, the timing and outcome of patent, antitrust and other litigation; the timing and scope of patents issued to our competitors; the FDA's pending inspection; what sanctions, if any, FDA may seek following its decision to place us in OAI status, including without limitation sanctions relating to any failure to comply with cGMP requirements and if and when the "hold" on our ANDA approvals will be lifted; manufacturing capacities, safety issues, output and quality processes; our dependence on a relatively small number of products; future product launches; our ability to develop and successfully commercialize new products; the loss of revenues from existing products; licensing revenues; whether we will be awarded any marketing exclusivity period and, if so, the precise dates thereof; government regulation generally; competition; our ability to meet the supply and manufacturing requirements of the First Horizon agreement; the success of our joint ventures; recent management changes and the potential loss of senior management and other key personnel; and the absence of certainty regarding the receipt of required regulatory approvals or the timing or terms of such approvals. Bupropion has no clinically significant impact on serotonin, a third brain chemical involved in mood
wellbutrin xl 150 mg regulation. For more information about Biovail, visit the company's Web site at www. Com For further information, please contact Ken Howling at 905-286-3000 or send inquiries to ir@biovail. Douglas Squires, Wellbutrin xl 150 mg biovail's Chief Executive Officer. A third patent, which would further strengthen Wellbutrin XL's(R) wellbutrin xl 150 mg intellectual property position, is currently under accelerated review by the U. The patent estate protecting Wellbutrin XL(R) consists
wellbutrin xl 150 mg of two formulation patents (U. On November 17, Wellbutrin xl 150 mg biovail announced that it received notification that Anchen Pharmaceuticals, Inc.
This entry was posted and is filed under 2FULLLINK.
You can follow any responses to this entry through the RSS 2.0 feed.
drumboy | Monday 17th August 2009 12:06:11 AM
Our actual results could differ materially from those discussed in, or implied by, these forward-looking statements.martin | Tuesday 18th August 2009 01:23:30 AM
Wellbutrin xl 150 mg (nasdaq:ipxl) today announced that Biovail Laboratories Inc. , a subsidiary of Biovail Corporation (NYSE:BVF) (TSX:BVF), has filed a lawsuit against the Company in the United States District Court, Eastern District of Pennsylvania (Philadelphia), alleging patent infringement related to IMPAX's filing for a generic version of Wellbutrin wellbutrin xl 150 mg xl(r).
friend | Monday 3rd August 2009 12:51:36 AM
For more information about Biovail, visit the company's Web site at www. Biovail. Com.
gwen | Friday 7th August 2009 11:58:16 PM
Such risks and uncertainties include, but are not limited to, IMPAX's ability to obtain sufficient capital to fund its operations, the difficulty of predicting FDA filings and approvals, consumer acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, IMPAX's ability to successfully develop and commercialize pharmaceutical products, IMPAX's reliance on key strategic alliances, the uncertainty of patent litigation, the availability of raw materials, the regulatory environment, dependence on patent and other protection for innovative products, exposure to product liability claims, fluctuations in operating results and wellbutrin xl 150 mg other risks detailed from time to time in IMPAX's filings with the Securities and Exchange Commission.
grace | Monday 17th August 2009 01:19:40 PM
Biovail is targeting the initiation of relevant studies in the first half Wellbutrin xl 150 mg of 2005, which could lead to a submission to the FDA by the second half of 2005.
grace | Friday 7th August 2009 12:01:03 PM
Patent numbers 6,143,327 and 6,096,341) listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations database (commonly referred to as the Orange Book).
oliver | Tuesday 25th August 2009 06:37:02 AM
-- Andrx Corporation (Nasdaq:ADRX) ("Andrx" or "Company") announced today that it has filed a patent infringement Wellbutrin xl 150 mg lawsuit in the U.hiroki | Wednesday 12th August 2009 09:02:54 AM
The hospital pharmacists weren't aware of the XL formulation, which was new at the time, and XL wasn't clearly written in the order. In another case, a prescriber ordered Wellbutrin XR, Wellbutrin xl 150 mg 150 mg daily, although no such product exists.
laba | Tuesday 11th August 2009 11:08:13 AM
Our actual results could differ materially from those discussed in, or implied by, these forward-looking statements.